{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,19]],"date-time":"2026-10-19T15:06:59Z","timestamp":1792422419962,"version":"4.5.0"},"reference-count":28,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2008,6,1]],"date-time":"2008-06-01T00:00:00Z","timestamp":1212278400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2008,6,1]],"date-time":"2008-06-01T00:00:00Z","timestamp":1212278400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100003725","name":"National Research Foundation of Korea","doi-asserted-by":"publisher","award":["2006-KRF-531-E00121"],"award-info":[{"award-number":["2006-KRF-531-E00121"]}],"id":[{"id":"10.13039\/501100003725","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["aaojournal.org","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Ophthalmology"],"published-print":{"date-parts":[[2008,6]]},"DOI":"10.1016\/j.ophtha.2008.02.013","type":"journal-article","created":{"date-parts":[[2008,4,25]],"date-time":"2008-04-25T12:50:34Z","timestamp":1209127834000},"page":"e33-e38","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":180,"title":["The Effect of Topical Bevacizumab on Corneal Neovascularization"],"prefix":"10.1016","volume":"115","author":[{"given":"Sang Woo","family":"Kim","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Byung Jin","family":"Ha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eung Kweon","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hungwon","family":"Tchah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tae-im","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ophtha.2008.02.013_bib1","doi-asserted-by":"crossref","first-page":"614","DOI":"10.1345\/aph.1H316","article-title":"Bevacizumab for neovascular ocular diseases","volume":"41","author":"Lynch","year":"2007","journal-title":"Ann Pharmacother"},{"key":"10.1016\/j.ophtha.2008.02.013_bib2","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1016\/j.mehy.2006.06.063","article-title":"A potential therapeutic strategy for inhibition of corneal neovascularization with new anti-VEGF agents","volume":"68","author":"Hosseini","year":"2007","journal-title":"Med Hypotheses"},{"key":"10.1016\/j.ophtha.2008.02.013_bib3","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1097\/00055735-200108000-00002","article-title":"Corneal neovascularization","volume":"12","author":"Chang","year":"2001","journal-title":"Curr Opin Ophthalmol"},{"key":"10.1016\/j.ophtha.2008.02.013_bib4","first-page":"264","article-title":"Corneal angiogenic privilege: angiogenic and antiangiogenic factors in corneal avascularity, vasculogenesis, and wound healing (an American Ophthalmological Society thesis)","volume":"104","author":"Azar","year":"2006","journal-title":"Trans Am Ophthalmol Soc"},{"key":"10.1016\/j.ophtha.2008.02.013_bib5","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1111\/j.1600-0420.2004.00312.x","article-title":"Vascular endothelial growth factor (VEGF) and its receptor VEGFR-2 in the regulation of corneal neovascularization and wound healing","volume":"82","author":"Gan","year":"2004","journal-title":"Acta Ophthalmol Scand"},{"key":"10.1016\/j.ophtha.2008.02.013_bib6","first-page":"961","article-title":"Vascular endothelial growth factor (rhVEGF 165) stimulates direct angiogenesis in the rabbit cornea","volume":"8","author":"Phillips","year":"1994","journal-title":"In Vivo"},{"key":"10.1016\/j.ophtha.2008.02.013_bib7","first-page":"18","article-title":"Requirement for vascular endothelial growth factor in wound- and inflammation-related corneal neovascularization","volume":"39","author":"Amano","year":"1998","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"10.1016\/j.ophtha.2008.02.013_bib8","doi-asserted-by":"crossref","first-page":"1258","DOI":"10.1345\/aph.1D470","article-title":"Bevacizumab: an angiogenesis inhibitor with efficacy in colorectal and other malignancies","volume":"38","author":"Zondor","year":"2004","journal-title":"Ann Pharmacother"},{"key":"10.1016\/j.ophtha.2008.02.013_bib9","doi-asserted-by":"crossref","first-page":"336","DOI":"10.3928\/1542-8877-20050701-15","article-title":"Optical coherence tomography findings after an intravitreal injection of bevacizumab (Avastin) for macular edema from central retinal vein occlusion","volume":"36","author":"Rosenfeld","year":"2005","journal-title":"Ophthalmic Surg Lasers Imaging"},{"key":"10.1016\/j.ophtha.2008.02.013_bib10","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1007\/s00347-007-1512-2","article-title":"Inhibition of angiogenesis in the anterior chamber of the eye","volume":"104","author":"Bock","year":"2007","journal-title":"Ophthalmologe"},{"key":"10.1016\/j.ophtha.2008.02.013_bib11","doi-asserted-by":"crossref","first-page":"1695","DOI":"10.1016\/j.ophtha.2006.05.064","article-title":"Intravitreal bevacizumab (Avastin) in the treatment of proliferative diabetic retinopathy","volume":"113","author":"Avery","year":"2006","journal-title":"Ophthalmology"},{"key":"10.1016\/j.ophtha.2008.02.013_bib12","doi-asserted-by":"crossref","first-page":"804","DOI":"10.1136\/bjo.2006.107912","article-title":"Inhibition of experimental corneal neovascularisation by bevacizumab (Avastin)","volume":"91","author":"Manzano","year":"2007","journal-title":"Br J Ophthalmol"},{"key":"10.1016\/j.ophtha.2008.02.013_bib13","doi-asserted-by":"crossref","first-page":"834","DOI":"10.1001\/archopht.125.6.834","article-title":"Topical bevacizumab therapy for corneal neovascularization","volume":"125","author":"DeStafeno","year":"2007","journal-title":"Arch Ophthalmol"},{"issue":"suppl","key":"10.1016\/j.ophtha.2008.02.013_bib14","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1634\/theoncologist.9-suppl_1-11","article-title":"Targeted therapy of colorectal cancer: clinical experience with bevacizumab","volume":"9","author":"Fernando","year":"2004","journal-title":"Oncologist"},{"key":"10.1016\/j.ophtha.2008.02.013_bib15","doi-asserted-by":"crossref","first-page":"1344","DOI":"10.1136\/bjo.2006.099598","article-title":"The International Intravitreal Bevacizumab Safety Study: using the internet to assess drug safety worldwide","volume":"90","author":"Fung","year":"2006","journal-title":"Br J Ophthalmol"},{"key":"10.1016\/j.ophtha.2008.02.013_bib16","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1007\/s00417-006-0411-6","article-title":"Intravitreal bevacizumab therapy for neovascular age-related macular degeneration: a pilot study","volume":"245","author":"Abraham-Marin","year":"2007","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"10.1016\/j.ophtha.2008.02.013_bib17","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1097\/01.iae.0000238561.99283.0e","article-title":"Intravitreal bevacizumab treatment of choroidal neovascularization secondary to age-related macular degeneration","volume":"26","author":"Spaide","year":"2006","journal-title":"Retina"},{"key":"10.1016\/j.ophtha.2008.02.013_bib18","doi-asserted-by":"crossref","first-page":"1379","DOI":"10.1136\/bjo.85.11.1379","article-title":"A new classification of ocular surface burns","volume":"85","author":"Dua","year":"2001","journal-title":"Br J Ophthalmol"},{"key":"10.1016\/j.ophtha.2008.02.013_bib19","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1111\/j.1442-9071.1987.tb00300.x","article-title":"Hierarchy of prognostic factors for corneal allograft survival","volume":"15","author":"Volker-Dieben","year":"1987","journal-title":"Aust N Z J Ophthalmol"},{"key":"10.1016\/j.ophtha.2008.02.013_bib20","doi-asserted-by":"crossref","first-page":"C905","DOI":"10.1152\/ajpcell.00200.2003","article-title":"Increased vascular endothelial growth factor may account for elevated level of plasminogen activator inhibitor-1 via activating ERK1\/2 in keloid fibroblasts","volume":"286","author":"Wu","year":"2004","journal-title":"Am J Physiol Cell Physiol"},{"key":"10.1016\/j.ophtha.2008.02.013_bib21","doi-asserted-by":"crossref","first-page":"1253","DOI":"10.1038\/sj.bjp.0704367","article-title":"Regulation of VEGF-induced endothelial cell PAF synthesis: role of p42\/44 MAPK, p38 MAPK and PI3K pathways","volume":"134","author":"Bernatchez","year":"2001","journal-title":"Br J Pharmacol"},{"key":"10.1016\/j.ophtha.2008.02.013_bib22","first-page":"2037","article-title":"Platelet-activating factor enhances urokinase-type plasminogen activator gene expression in corneal epithelium","volume":"37","author":"Tao","year":"1996","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"10.1016\/j.ophtha.2008.02.013_bib23","doi-asserted-by":"crossref","first-page":"3332","DOI":"10.1167\/iovs.02-1280","article-title":"Up-regulation of urokinase-type plasminogen activator in corneal epithelial cells induced by wounding","volume":"44","author":"Watanabe","year":"2003","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"10.1016\/j.ophtha.2008.02.013_bib24","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1007\/PL00000615","article-title":"The plasminogen activator system: biology and regulation","volume":"56","author":"Irigoyen","year":"1999","journal-title":"Cell Mol Life Sci"},{"key":"10.1016\/j.ophtha.2008.02.013_bib25","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1055\/s-0037-1615846","article-title":"Proteolysis, cell adhesion, chemotaxis, and invasiveness are regulated by the u-PA-u-PAR-PAI-1 system","volume":"82","author":"Blasi","year":"1999","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.ophtha.2008.02.013_bib26","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1016\/j.thromres.2007.03.024","article-title":"VEGF increases the fibrinolytic activity of endothelial cells within fibrin matrices: involvement of VEGFR-2, tissue type plasminogen activator and matrix metalloproteinases","volume":"121","author":"Ratel","year":"2007","journal-title":"Thromb Res"},{"key":"10.1016\/j.ophtha.2008.02.013_bib27","doi-asserted-by":"crossref","first-page":"976","DOI":"10.1183\/09031936.00152106","article-title":"Inhibition of PDGF, VEGF and FGF signalling attenuates fibrosis","volume":"29","author":"Chaudhary","year":"2007","journal-title":"Eur Respir J"},{"key":"10.1016\/j.ophtha.2008.02.013_bib28","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.preteyeres.2006.09.002","article-title":"Ocular neovascularization: implication of endogenous angiogenic inhibitors and potential therapy","volume":"26","author":"Zhang","year":"2007","journal-title":"Prog Retin Eye Res"}],"container-title":["Ophthalmology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0161642008001760?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0161642008001760?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,27]],"date-time":"2025-09-27T13:57:09Z","timestamp":1758981429000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0161642008001760"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2008,6]]},"references-count":28,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2008,6]]}},"alternative-id":["S0161642008001760"],"URL":"https:\/\/doi.org\/10.1016\/j.ophtha.2008.02.013","relation":{},"ISSN":["0161-6420"],"issn-type":[{"value":"0161-6420","type":"print"}],"subject":[],"published":{"date-parts":[[2008,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The Effect of Topical Bevacizumab on Corneal Neovascularization","name":"articletitle","label":"Article Title"},{"value":"Ophthalmology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ophtha.2008.02.013","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2008 American Academy of Ophthalmology. Published by Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}